Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

NCT01909453 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01909453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01909453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
September 12, 2013
Completion date
September 3, 2024
Enrollment
921 (actual)
Sites
282

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma